GENENTECH GROWTH HORMONE SALES FORCE RETRAINING TO BEGIN IN 1997 AS PART OF CORRECTION ACTION PROGRAM STEMMING FROM AD DIVISION LETTER ON PROTROPIN
Genentech will retrain its sales force beginning in 1997 as part of a corrective campaign agreed upon by the company and FDA following a December 1995 letter from the Division of Drug Marketing, Advertising, and Communications concerning Genentech's promotion of Protropin (somatrem for injection).
You may also be interested in...
Genentech is responding to a subpoena regarding its promotions of the oncologic agent Rituxan
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011